Imagion Biosystems and Patrys Limited to Collaborate on Brain Tumor Imaging

Imagion Biosystems is pleased to announce a partnership with the ASX-listed therapeutic antibody development company Patrys Limited. The collaborative research…


Quarterly Activity Report — Period ending 31 March 2021

Imagion Biosystems is pleased to report that we closed the first quarter of FY2021 maintaining a strong cash balance and having added a new study site for our…


Imagion Biosystems March 2021 Investor Newsletter

Imagion Biosystems is pleased to provide its investors with its March 2021 Investor Newsletter. The newsletter details recent new company developments and…


Imagion Receives CSIRO Federal Government Grant for Prostate Cancer Project

Imagion Biosystems is pleased to announce it is a proud recipient of an Innovations Connections grant from the Australian Government’s Department of Industry,…


Imagion Biosystems 2020 Full Year Results

2020 Highlights: MagSense® HER2 breast cancer Phase I study initiated Collaboration with Siemens Healthineers explores MagSense® nanoparticles using MRI Total…


Quarterly Activity Report for 31 December 2020 — Appendix 4C

Imagion Biosystems today released its Appendix 4C Quarterly Cashflow report and update on Company activities for the quarter ending 31 December 2020 (Q4…


Imagion Biosystems December 2020 Investor Newsletter

Imagion Biosystems is pleased to provide its investors with its December 2020 Investor Newsletter. The newsletter details recent new company developments and…


First In-human Study Update: Study Open for Enrolment

Imagion Biosystems is pleased to announce that Monash Health has been established as the first clinical site and is ready to commence enrolment of patients for…


Proposed Issue of Securities — Appendix 3B

Imagion Biosystems has announced a Proposed Issue of Securities. Read the announcement.


IBX Raises $6M in Placement

Highlights: $6M raised in a heavily oversubscribed placement at 8.5c per share – a 6% discount to the 30-day VWAP. Placement strongly supported by…